Aspect Biosystems To Present New Data At International Pancreas And Islet Transplant Association (Ipita) Congress 2021

Bioprinted pancreatic tissues successfully regulate blood glucose in animal models of type 1 diabetes

Vancouver, BC, Canada, October 13, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present the Company’s latest data on its bioprinted pancreas therapeutic program at the International Pancreas and Islet Transplant Association Congress 2021, held virtually from October 20-23, 2021. This data highlights successful regulation of blood glucose in animal models of type 1 diabetes for 90 days post-implantation.